Cases & Deals

Pfizer acquires Serenex, Inc

Client(s) Pfizer, Inc.

Jones Day acted as tax counsel to Pfizer, Inc. in its acquisition of Serenex, Inc., a privately-held biotechnology company. As per the agreement, Pfizer acquired the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase 1 trials for the potential treatments of tumors and hematological malignancies.